research microscope image

Research Successes

LLSC - Funded Researcher Spotlights

The Leukemia & Lymphoma Society of Canada (LLSC) and The Leukemia & Lymphoma Society in the US (LLS) fund research across the continuum, from basic research through clinical trials, from bench to bedside. To date, we have invested more than $1 billion in research to advance therapies and save lives. Research grants have funded many of today's most promising advances, including targeted therapies and immunotherapies and some of the therapies first approved for blood cancer patients are now helping patients with other types of cancers and other serious diseases.

Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled since 1960.

Find out more on the world's most renowned blood cancer researchers and how LLSC & LLS support help make it happen.

 

Donate Today      

Research Programs

lab test tube image

Academic Grants

The Leukemia & Lymphoma Society of Canada's (LLSC's) academic grants support and encourage basic and translational leukemia, lymphoma, Hodgkin's disease and myeloma research. LLSC investigators are outstanding scientists at the forefront of leukemia, lymphoma, Hodgkin's disease and myeloma research at centers throughout Canada. We award academic grants for studies that range from basic blood cancer resear...

Operating Grants

DEADLINE: Midnight EST, February 10, 2017   We are pleased to advise you that The Leukemia & Lymphoma Society of Canada (LLSC) is accepting grant applications in the following categories: Operating Grants New Idea Award  LLSC is proud to announce the first year of the New Idea Award, a grant program designed to identify novel research strategies with a potential for high impact on a...

Scientific Review Panel

The Leukemia & Lymphoma Society of Canada's (LLSC's) 2015 Scientific Review Panel is comprised of leading experts in their fields. Members volunteer their time to LLSC and receive no compensation for their generous support. They provide guidance to LLSC's research grant process. The Panel changes yearly and this list will be updated upon completion of the current year's grant re...

Medical and Scientific Advisory Committee

The Leukemia & Lymphoma Society of Canada's (LLSC's) Medical & Scientific Advisory Committee is comprised of leading experts in their fields. Members volunteer their time to LLSC and receive no compensation for their generous support. The committee's role is to advise the Board of Directors on a range of issues, including periodically reviewing LLSC's medical affairs and providing guida...

scientist testing at lab image

Celator Announces VYXEOS™ Phase 3 Trial - Statistically Significa...

Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival -- First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk AML --
-- NDA submission for VYXEOS planned for later this year -...

scientist testing at lab image

DARZALEX™ Approved by Health Canada for Treatment of Multiple Mye...

DARZALEX™ (daratumumab) Approved by Health Canada as the First Human Anti-CD38 Monoclonal Antibody for the Treatment of Multiple Myeloma TORONTO, June 30, 2016 /CNW/ - Janssen Inc. announced today Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior line...